Shukra Pharmaceuticals
Shukra Pharmaceuticals Share Price Chart
Shukra Pharmaceuticals last traded at ₹66.40 (2026-10-13). Over the past month the stock moved +23.2%, three months the stock moved +143.8%, year the stock moved +112.5%. Its closing range over 52 weeks is ₹27.23 – ₹72.85, with the latest close 8.9% below the high.
Closing prices up to 2026-10-13.
About Shukra Pharmaceuticals
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
Business Overview:[1][2] SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Shukra Pharmaceuticals reported sales of ₹24.00 crore (+380.0%) and net profit of ₹15.00 crore (+1400.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 24.00 | 21.00 | 90.00 | 15.00 | 0.34 |
| Mar 2026 | 6.00 | 1.00 | 11.00 | -2.00 | -0.04 |
| Dec 2025 | 39.00 | 27.00 | 69.00 | 20.00 | 0.46 |
| Sep 2025 | 6.00 | 0.00 | -7.00 | 2.00 | 0.05 |
| Jun 2025 | 5.00 | 1.00 | 24.00 | 1.00 | 0.02 |
| Mar 2025 | 13.00 | 7.00 | 55.00 | 5.00 | 0.12 |
| Dec 2024 | 11.00 | 4.00 | 37.00 | 3.00 | 0.07 |
| Sep 2024 | 6.00 | 1.00 | 12.00 | 1.00 | 0.01 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -76.0% | -42.1% | +18.2% | +66.7% | +0.0% | +254.5% | -53.8% | +380.0% |
| Operating profit growth | -80.0% | -60.0% | +75.0% | +0.0% | -100.0% | +575.0% | -85.7% | +2000.0% |
| Net profit growth | -80.0% | -66.7% | +25.0% | – | +100.0% | +566.7% | -140.0% | +1400.0% |
| EPS growth | -90.9% | -68.2% | +33.3% | +100.0% | +400.0% | +557.1% | -133.3% | +1600.0% |
| OPM % | 12.0% | 37.0% | 55.0% | 24.0% | -7.0% | 69.0% | 11.0% | 90.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Shukra Pharmaceuticals reported sales of ₹57.00 crore (+74.9%) and net profit of ₹22.00 crore (+129.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 57.00 | 29.00 | 51.00 | 22.00 | 0.50 |
| Mar 2025 | 32.59 | 12.72 | 39.03 | 9.58 | 0.22 |
| Mar 2024 | 74.57 | 19.40 | 26.02 | 18.54 | 0.42 |
| Mar 2023 | 58.83 | 5.36 | 9.11 | 4.41 | 0.10 |
| Mar 2022 | 20.48 | 2.89 | 14.11 | 0.75 | 0.02 |
| Mar 2021 | 11.18 | 1.44 | 12.88 | 0.19 | 0.00 |
| Mar 2020 | 11.84 | 1.54 | 13.01 | 0.04 | 0.00 |
| Mar 2019 | 5.66 | 1.65 | 29.15 | 0.46 | 0.01 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +6.0% | +109.2% | -5.6% | +83.2% | +187.3% | +26.8% | -56.3% | +74.9% |
| Operating profit growth | +2.5% | -6.7% | -6.5% | +100.7% | +85.5% | +261.9% | -34.4% | +128.0% |
| Net profit growth | -13.2% | -91.3% | +375.0% | +294.7% | +488.0% | +320.4% | -48.3% | +129.6% |
| EPS growth | +0.0% | -100.0% | – | – | +400.0% | +320.0% | -47.6% | +127.3% |
| OPM % | 29.2% | 13.0% | 12.9% | 14.1% | 9.1% | 26.0% | 39.0% | 51.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Shukra Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Shukra Pharmaceuticals fixes record date for ₹0.01 per share final dividend - scanx.trade
-
Shukra Pharmaceuticals Q1 Results: Net Profit Rises 13.6x YoY to ₹1,502.98 Lakh - scanx.trade
-
Shukra Pharmaceuticals approves preferential issue of warrants - scanx.trade
-
Shukra Pharmaceuticals Q3 Net Profit Surges 543% YoY to ₹203.65 Crores - scanx.trade
-
Shukra Pharmaceuticals Q3 Net Profit Surges 543% YoY to ₹203.65 Crores - scanx.trade
-
Shukra Pharmaceuticals Q3 Net Profit Surges 543% YoY to ₹203.65 Crores - scanx.trade
-
Shukra Pharmaceuticals Q3 Net Profit Surges 543% YoY to ₹203.65 Crores - scanx.trade
-
Shukra Pharmaceuticals Q3 Net Profit Surges 543% YoY to ₹203.65 Crores - scanx.trade
-
Shukra Pharmaceuticals reports consolidated net loss of Rs 1.72 crore in the March 2026 quarter - Business Standard
-
Shukra Pharmaceuticals Reports FY26 Audited Results; Net Profit More Than Doubles, Board Recommends Dividend and Approves Warrant Conversion - scanx.trade
Frequently Asked Questions
What is Shukra Pharmaceuticals's current stock price?
Shukra Pharmaceuticals shares were last quoted at ₹66.40 (-0.9% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Shukra Pharmaceuticals?
Shukra Pharmaceuticals has a price-to-earnings (P/E) ratio of 72.56 and a price-to-book (P/B) ratio of 23.88. The industry P/E is 53.33.
What is the 52-week high and low of Shukra Pharmaceuticals?
The 52-week high of Shukra Pharmaceuticals is ₹65.26 and the 52-week low is ₹26.30.
What is the market cap of Shukra Pharmaceuticals?
The market capitalisation of Shukra Pharmaceuticals is about ₹2,446.43 crore.
How did Shukra Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Shukra Pharmaceuticals reported sales of ₹24.00 crore (+380.0%) and net profit of ₹15.00 crore (+1400.0%), compared with the same quarter last year.
Is Shukra Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Shukra Pharmaceuticals has a 3-year ROE of 28.00%, 3-year profit growth of 71.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Shukra Pharmaceuticals?
Promoters hold about 51.15% of Shukra Pharmaceuticals.
Which sector does Shukra Pharmaceuticals belong to?
Shukra Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.